Press releases
Dr. Tsutomu Suzuki is a professor at the department of chemistry and biotechnology in University of Tokyo, Japan.
Read more
Publication provides timely and critical reviews of important topics in medicinal chemistry
Read more
STORM Therapeutics’ will be attending the following virtual conferences.
Read more
STC-15, the first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies.
Read more
Presentations will showcase the activity of first-in-class METTL3 inhibitors in a range of solid tumours, building on prior POC data in AML. Establishes new therapeutic opportunities for METTL3 inhibitors across a wide range of solid cancers
Read more